{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wan D"],"funding":["Major Science and Technology Project of Hainan Province","National Major Science and Technology Projects of China","National Key Research and Development Program of China","Cancer Foundation of China"],"pagination":["200975"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11999459"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["33(2)"],"pubmed_abstract":["The combination of oncolytic viruses (OVs) with other immunotherapies, such as immunostimulatory therapies, is a current research hotspot; however, optimizing their therapeutic potential remains to be fully explored. Here, we designed a novel oncolytic herpes simplex virus 2 expressing Fms-like tyrosine kinase 3 ligand (OH2-FLT3L), which induces an antitumor cytotoxic T cell immune response by activating dendritic cells (DCs). We found that OH2-FLT3L specifically infects tumor cells, induces immunogenic cell death (ICD), and releases a large number of tumor-specific antigens, which bound to danger signals and facilitated antigenic cross-presentation by DCs, significantly enhancing T cell activation and function. Experimental results showed that OH2-FLT3L significantly increased the proport"],"journal":["Molecular therapy. Oncology"],"pubmed_title":["Engineered oncolytic virus OH2-FLT3L enhances antitumor immunity via dendritic cell activation."],"pmcid":["PMC11999459"],"funding_grant_id":["2023YFC3403300","H092301","2022ACA001"],"pubmed_authors":["Cheng S","Xu L","Zhang W","Yang Z","Zhang K","Zhang X","Liu B","Xie P","Zhang Q","Wan D"],"additional_accession":[]},"is_claimable":false,"name":"Engineered oncolytic virus OH2-FLT3L enhances antitumor immunity via dendritic cell activation.","description":"The combination of oncolytic viruses (OVs) with other immunotherapies, such as immunostimulatory therapies, is a current research hotspot; however, optimizing their therapeutic potential remains to be fully explored. Here, we designed a novel oncolytic herpes simplex virus 2 expressing Fms-like tyrosine kinase 3 ligand (OH2-FLT3L), which induces an antitumor cytotoxic T cell immune response by activating dendritic cells (DCs). We found that OH2-FLT3L specifically infects tumor cells, induces immunogenic cell death (ICD), and releases a large number of tumor-specific antigens, which bound to danger signals and facilitated antigenic cross-presentation by DCs, significantly enhancing T cell activation and function. Experimental results showed that OH2-FLT3L significantly increased the proport","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jun","modification":"2026-07-15T04:59:05.226Z","creation":"2026-06-30T03:07:07.538Z"},"accession":"S-EPMC11999459","cross_references":{"pubmed":["40236993"],"doi":["10.1016/j.omton.2025.200975"]}}